Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Share :
Published: 4 Jun 2022
Views: 90
Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Dr Hope Rugo announces the use of sacituzumab govitecan (trodelvy) an antibody-drug conjugate which resulted in longer progression-free survival compared to the physician’s choice of chemotherapy in patients who have received many prior therapies and who had hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer.

She explains almost one in three cases of early-stage breast cancer eventually becomes metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%.

She continues to discuss the treatment for HR+/HER2- metastatic breast cancer initially includes sequential endocrine therapy combined with targeted agents, and as the disease becomes resistant to endocrine-based therapy, treatment is limited to sequential single-agent chemotherapy with an increasingly shorter duration of benefit.

Dr Rugo expands the discussion by explaining the OS and long-term safety endpoints the patients in the study followed.

Watch the interview here

Read the article here

Watch the comment video here